Removab: antibody treatment for malignant ascites

Removab (catumaxomab) is now available to treat malignant ascites due to EpCAM-positive carcinomas where standard therapy is not available or not feasible.

Catumaxomab is a hybrid rat-mouse monoclonal antibody that has binding sites for the epithelial cell adhesion molecule (EpCAM) and CD3, a component of the T cell receptor. It stimulates a range of immune responses against tumour cells.

A randomised, open-label trial compared catumaxomab (as 4 intraperitoneal infusions) plus paracentesis with paracentesis alone in 258 patients with symptomatic malignant ascites due to EpCAM-positive carcinomas. Median puncture-free survival, the primary endpoint, was significantly longer with catumaxomab than with drainage alone (46 days vs 11 days; p<0.0001). Median time to the next therapeutic puncture was also significantly increased in the catumaxomab group compared with the drainage-alone group (77 days versus 13 days; p<0.0001) and there was a trend towards increased overall survival with catumaxomab (72 days vs 68 days; p=0.0846).

View Removab drug record

Further Information: Fresenius Kabi

MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register for MIMS

Want to keep getting your free copy of MIMS? GPs will need to renew their subscription to keep receiving MIMS and GP for free in 2015. You can do this online now – take 2 minutes, and make sure you keep your free MIMS access!


MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.